bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: N O S A J J M A M F J
2013: D N

 
  Other news for:
Crohn Disease
Ulcer
 Resources from HONselect
FDA OKs New Drug for Hard-to-Treat Colitis and Crohn's
Injections of Entyvio may help when standard therapy for the digestive disorders has failed

By Robert Preidt

WEDNESDAY, May 21, 2014 (HealthDay News) -- A new drug to treat adults with ulcerative colitis and Crohn's disease has been approved by the U.S. Food and Drug Administration.

The agency said Tuesday that injections of Entyvio (vedolizumab) can be used to treat patients with moderate to severe ulcerative colitis and Crohn's disease who have had poor responses to one or more of the current standard therapies: corticosteroids, immunomodulators, or tumor necrosis factor blocker medications.

The FDA's approval of the new drug is based on two clinical trials of about 900 patients with ulcerative colitis, and three clinical trials of about 1,500 patients with Crohn's disease.

Ulcerative colitis causes inflammation and ulcers in the inner lining of the large intestine and can lead to abdominal discomfort, bleeding and diarrhea. It affects about 620,000 Americans. Crohn's can cause inflammation and irritation in any part of the digestive tract. It affects more than 500,000 Americans.

"Ulcerative colitis and Crohn's disease are debilitating diseases that impact the quality of life of those who have these conditions," Dr. Amy Egan, acting deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"Although there is no cure for these conditions, [Tuesday's] approval provides an important new treatment option for patients who have had an inadequate response to conventional therapy to help control their symptoms," she added.

Entyvio is a type of drug called an "integrin receptor antagonist." These drugs improve the function of cell-to-cell interactions, the FDA said. Another type of integrin receptor antagonist -- Tysabri (natalizumab) -- has been linked with a rare and often fatal infection of the central nervous system called progressive multifocal leukoencephalopathy (PML).

No cases of PML occurred in patients taking part in the clinical trials of Entyvio. But the risk for patients taking the new drug remains unclear and doctors should monitor patients who are taking Entyvio for any signs of PML, the FDA said.

The FDA told Entyvio's maker, Takeda Pharmaceuticals America Inc., that it must conduct a post-approval study to further investigate the risk of PML among patients taking Entyvio.

In the clinical trials, the most common side effects among patients taking Entyvio included headache, joint pain, nausea and fever. The most serious side effects included major infections, injection-related reactions and liver toxicity.

More information

The U.S. National Library of Medicine has more about ulcerative colitis and Crohn's disease.

SOURCE: U.S. Food and Drug Administration, news release, May 20, 2014

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=688061

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Ulcer
Drug Evaluation
Risk
Infection
Affect
Evaluation Studies
Inflammation
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact